Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(3)

Phase 2(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06734286Not ApplicableRecruiting

Working Memory Training in Patients with Mild Cognitive Impairment

Role: collaborator

NCT04840069Phase 2Unknown

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

Role: collaborator

NCT05479136Phase 3Unknown

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

Role: collaborator

NCT02618382Phase 4Completed

A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population

Role: collaborator

NCT02924194Not ApplicableTerminated

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

Role: collaborator

NCT01593267Not ApplicableUnknown

Barrow Ruptured Aneurysm Trial

Role: collaborator

NCT02469896Phase 2Completed

A Trial of Tocilizumab in ALS Subjects

Role: collaborator

NCT01421420Unknown

Alzheimer's Disease Core Center

Role: collaborator

NCT00217321Unknown

Parkinson's Disease Registry of the Muhammad Ali Parkinson Center

Role: collaborator

All 9 trials loaded